This industry profile provides a five-year forecast for Canada’s Pharmaceutical Products Industry.
Canadian Industrial Profile: Pharmaceutical Products—Winter 2017
Canadian Industrial Profile: Pharmaceutical Products—Winter 2017
Industry Economic Analysis
$660.00
Aging Population—As Canada’s population continues to age rapidly, spending on pharmaceutical products will continue to increase steadily.
CETA Patent Terms—Intellectual property provisions in the Comprehensive and Economic Trade Agreement (CETA) should extend patent terms. This will slow the introduction of generics to the Canadian market, benefitting producers of patented drugs.
R&D Spending—Research and development expenditures fell to 5.1 per cent in 2015, compared with an average of 7.7 per cent over the past decade, which could hamper the industry’s ability to capitalize on rising global demand.
Customers Who Downloaded This Also Liked
14 min read
18 min read
Require an accessible version of this research?
Upon request, Signal49 Research offers accessible versions of research. Please contact us to request your accessible version.
Learn more about our accessibility policies.
Effective January 26, 2026, AERIC Inc./Signal49 Research discontinued use of ‘The Conference Board of Canada’ name, logo and branding, which had been used by AERIC Inc./Signal49 Research under license from The Conference Board, Inc. The Conference Board, Inc. and its licensees, which are not affiliated with Signal49 Research, own all right, title and interest in THE CONFERENCE BOARD name and trademarks in Canada and have the exclusive right to their use in Canada since January 26, 2026.
